Advertisement
Advertisement
FHTX
Foghorn Therapeutics Inc. Common Stock
4.44
USDSponsored
+0.24
+5.71%
May 08, 16:00 UTC -4
Closed
Pre-Market
4.41
-0.03
-0.77%
FHTX Earnings Reports
Positive Surprise Ratio
FHTX beat 14 of 22 last estimates.
64%
Next Report
Today BMO
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$7.59M
/-$0.30
Implied change from Q4 25 (Revenue/ EPS)
-17.95%
/-11.76%
Implied change from Q1 25 (Revenue/ EPS)
+27.47%
/--
Foghorn Therapeutics Inc. Common Stock earnings per share and revenue
On Mar 11, 2026, FHTX reported earnings of -0.34 USD per share (EPS) for Q4 25, missing the estimate of -0.25 USD, resulting in a -34.76% surprise. Revenue reached 9.25 million, compared to an expected 9.69 million, with a -4.57% difference. The market reacted with a +2.48% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 8 analysts forecast an EPS of -0.30 USD, with revenue projected to reach 7.59 million USD, implying an decrease of -11.76% EPS, and decrease of -17.95% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.38
Actual
-$0.45
Surprise
-16.10%
Bicara Therapeutics Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$0.66
Actual
-$0.93
Surprise
-39.98%
Certara, Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
$0.10
Actual
$0.09
Surprise
-17.36%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
PUMA BIOTECHNOLOGY INC
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.04
Surprise
+69.83%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
Apogee Therapeutics, Inc. Common Stock
Report Date
May 11, 2026 For Q1 26
Estimate
-$1.12
Actual
-$1.06
Surprise
+5.65%
Edgewise Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.49
Actual
-$0.46
Surprise
+7.33%
FAQ
What were Foghorn Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Foghorn Therapeutics Inc. Common Stock reported EPS of -$0.34, missing estimates by -34.76%, and revenue of $9.25M, -4.57% below expectations.
How did the market react to Foghorn Therapeutics Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 2.48%, changed from $5.64 before the earnings release to $5.78 the day after.
When is Foghorn Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Foghorn Therapeutics Inc. Common Stock's next earnings report?
Based on 8
analysts, Foghorn Therapeutics Inc. Common Stock is expected to report EPS of -$0.30 and revenue of $7.59M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement